Differences between lorlatinib/lorlatinib and aletinib in the treatment of non-small cell lung cancer

Lorlatinib/ Lorlatinib and alectinib are targeted therapies for ALK-positive non-small cell lung cancer (NSCLC). Although they have the same goals, they have significant differences in drug generations, indications and therapeutic effects.

1. Drug generations and indications:

1. Alectinib: It is a second-generation ALK inhibitor. It is often used as a first-line treatment option, especially for patients with ALK-positive non-small cell lung cancer. Widely recognized for its effective control of brain metastasis.

2. Lorlatinib: Classified as a third-generation ALK inhibitor. It is mainly suitable for patients who are resistant to early ALK inhibitors. It provides new treatment opportunities for patients with advanced disease or those who have failed other treatments.

2. Ability to penetrate the blood-brain barrier:

1. Alectinib: Although it has a certain effect on brain metastasis, its ability to penetrate the blood-brain barrier may be weaker than lorlatinib.

2. Lorlatinib: It has excellent ability to penetrate the blood-brain barrier and is particularly important for the treatment of brain metastases.

3. Clinical efficacy:

1. Alectinib: In clinical trials, compared with crizotinib, it significantly improved the progression-free survival (PFS) of patients. The ALEX study showed that aletinib reduced the risk of disease progression or death by 53%, and did not reach the median PFS, showing that the time to disease control was prolonged.

2. Lorlatinib: It has shown significant efficacy in patients who have failed previous ALK inhibitor treatment. After patients received lorlatinib treatment, the objective response rate (ORR) was significant, and the proportion of patients with partial or complete response was high. The median duration of response (DOR) also suggests that lorlatinib may bring long-term benefit to patients with ALK-positive NSCLC.

In summary, lorlatinib and alectinib have their own characteristics in the treatment of non-small cell lung cancer. As a second-generation drug, alectinib has performed well in first-line treatment, while lorlatinib has provided new hope for drug-resistant patients with its third-generation drug properties and potent treatment of brain metastases.